ClinicalTrials.gg
Status unknownNCT02671318StopCMVUpdated Aug 17, 2016

Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence

A Phase 4 interventional study of Drug conversion to sirolimus and Maintenance of the current regimen in Cytomegalovirus Infections, sponsored by Hospital do Rim e Hipertensão. Status unknown at 1 site in Brazil. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-17.

Sponsored by Hospital do Rim e Hipertensão · Phase 4, Interventional, and Prevention

How we know

The sponsor has not verified this record recently (last verified Aug 2016), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
250
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Cytomegalovirus Infections with a site in Brazil — 1 open to participants now, 1 under way, none of them phase 3. Cytomegalovirus Infections · Brazil.

Started
2015
the only one that year
Phase 4
5 of 12
none open now
Registered
9th of 12
by date
Lead sponsor
3 of 12
Hospital do Rim e Hipertensão

Among the 12 studies in Cytomegalovirus Infections with a site in Brazil, this one is the only one that started in 2015, is one of 5 in phase 4, and was the 9th registered.

Cytomegalovirus Infections

370 studies on the registry are indexed under Cytomegalovirus Infections; 57 are open to participants now.

Browse Cytomegalovirus Infections studies →

Open to participants now

1 of the 12 studies in Cytomegalovirus Infections with a site in Brazil is open now. Recruiting first, the newest first:

A study can be open while its sites in Brazil have not opened yet or have stopped. Only those recruiting at a site in Brazil →

Who these studies take

Of the 35 Cytomegalovirus Infections studies recruiting now, 20 (57%) set no upper age limit and 13 (37%) stop at 75 or younger; 19 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Cytomegalovirus Infections with a site in Brazil, or all of them as a file.
02

Study summary

Cytomegalovirus is the most important opportunistic infection after kidney transplant, with increased in mortality, morbidity and higher costs of transplantation. Despite the favorable efficacy (lower acute rejection) results of the most worldwide used regime, tacrolimus, mycophenolate and prednisone, or the investigators local common regimen, tacrolimus, azathioprine and prednisone, this combinations are associated with higher incidence of cytomegalovirus infection, disease and recurrence.

Namely, sirolimus use is associated with decreased risk of cytomegalovirus infection/disease, and there is not a prospective cohort to evaluate the conversion to sirolimus efficacy to decrease the cytomegalovirus infection recurrence.

Given this, the investigators propose a study of their own initiative that attends local needs: evaluate the conversion to sirolimus efficacy in decrease the cytomegalovirus recurrence after kidney transplant.

Read the detailed description

This protocol is a prospective, randomized, single center, designed to evaluate incidence of cytomegalovirus recurrence infection/disease in two immunosuppressive regimens, after the first episode of cytomegalovirus: (1) conversion of azathioprine or mycophenolate to sirolimus, in a regimen wih low doses tacrolimus and prednisone; ( 2) Maintenance of the current regimen during the first episode of cytomegalovirus infection ( azathioprine or mycophenolate, in combination to tacrolimus or prednisone). Our hypothesis is that conversion from azathioprine or sodium mycophenolate to sirolimus, with low doses of tacrolimus, and prednisone results in lower recurrence of cytomegalovirus infection/disease in kidney transplant recipients.

03

Conditions studied

  • Cytomegalovirus Infections

Keywords

  • cytomegalovirus
  • sirolimus
  • cytomegalovirus recurrence
  • kidney transplant
  • conversion
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult kidney transplant recipients > 18 y.o.
  • Kidney Transplant recipients, after the first episode of cytomegalovirus infection, using the current regimen: azathioprine or mycophenolate, tacrolimus and prednisone.

Exclusion criteria

Exclusion Criteria:

  • Re-transplant;
  • Patients with any panel reactive antibody (PRA) equal to or above 50%, class I or class II;
  • Acute rejection episode in the last 30 days, or episode > 2A in the Banff criteria;
  • (MDRD) \< 40 ml/min;
  • Proteinuria > 0,5 g/l;
  • \< 10 g/l and/or leucocytes \< 4000 cels/mm3 and/or \< 150.000 cels/mm3;
  • Triglycerides > 500 mg/dl with or without use of fibrate;
  • Cholesterol total > 300 mg/dl with or without use of statin;
  • Hepatic abnormalities;
  • Significant periphery edema;
  • Pulmonary abnormalities or breast x-ray abnormalities;
  • Hyper sensibility to sirolimus formula;
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
250 participants (estimated)

Study arms

  • Active comparator
    Drug conversion to sirolimus

    Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.

    Drug: Drug conversion to sirolimus

  • Active comparator
    Maintenance of the current regimen

    Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.

    Drug: Maintenance of the current regimen

Interventions

  • DrugSirolimusStudies of SirolimusSirolimus pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.

    Also known as: Rapamune

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.

    Also known as: Myfortic, Immuran

06

What researchers measure

Primary outcomes

  1. Cytomegalovirus infection/disease recurrence

    Cytomegalovirus infection/disease recurrence

    Time frame: One year

07

Study locations

1 of 1 sites recruiting
  • Hospital do Rim
    São Paulo, 04037-003, Brazil
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2015, a primary completion of Dec 2019 and a completion of Aug 2020. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2016
First posted
Feb 2, 2016
Start
Sep 2015
Primary completionEst.
Dec 2019
CompletionEst.
Aug 2020
Last update
Aug 17, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02671318
Lead sponsor
Hospital do Rim e Hipertensão
Responsible party
Geovana Basso (MD, Hospital do Rim e Hipertensão) — Principal investigator
First posted
Feb 2, 2016
Start date
Sep 2015
Primary completion
Dec 2019 (estimated)
Completion
Aug 2020 (estimated)
Last update
Aug 17, 2016

Study contacts

Geovana Basso, MD
Contact
geovana_basso@hotmail.com
+55 11 50878000
Geovana Basso, MD
principal investigator · Nephrology Division, Hospital do Rim, Federal University of São Paulo, Brazil
Helio Tedesco Silva Junior, PhD
study chair · Nephrology Division, Hospital do Rim, Federal University of São Paulo, Brazil
Claudia Rosso felipe, PhD
study chair · Nephrology Division, Hospital do Rim, Federal University of São Paulo, Brazil
Leonardo V. Riella, PhD
study chair · Brigham and Women's Hospital, US.
Jose O. Medina Pestana, PhD
study chair · Nephrology Division, Hospital do Rim, Federal University of São Paulo, Brazil

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sirolimus · Mycophenolic Acid

Start the discussion